Up­dat­ed: In sur­prise turn, FDA ad­comm votes in fa­vor of Arde­lyx CKD drug de­spite agency ques­tions

Af­ter the FDA re­ject­ed and ques­tioned Arde­lyx’s po­ten­tial drug for the con­trol of serum phos­pho­rus lev­els in adults with chron­ic kid­ney dis­ease on dial­y­sis, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.